Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case — Update
By Elias Schisgall
Halozyme was granted a preliminary injunction that would prevent Merck & Co. from distributing a formulation of Keytruda in Germany as part of a patent-infringement dispute over the cancer treatment.
The Munich Regional Court ruled Thursday there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
The ruling applies only to the subcutaneous formulation of Merck & Co.'s treatment, rather than the intravenous formulation, which Halozyme said isn't covered by its own patents.
In a statement, a Merck & Co. spokesperson said the Rahway, N.J., company disagrees with the court's ruling.
"We consider Halozyme's patent to be invalid globally and their allegation of infringement to be without merit," the spokesperson said. "We are confident in our legal position and believe that, ultimately, we will prevail in the courts."
Merck & Co. separately launched nullity proceedings against Halozyme's patent in German Federal Patent Court in August.
Halozyme also has brought legal action against Merck & Co. in New Jersey federal courts to block the company from distributing Keytruda SC in the U.S.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
December 04, 2025 15:44 ET (20:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States